INSIGHTEC's MR-Guided Focused Ultrasound Treatment for Essential Tremor Now Covered By Medicare in 25 States

News provided by

Oct 01, 2018, 09:00 ET

HAIFA, Israel and MIAMI, October 1, 2018 /PRNewswire/ --

Expansion of Medicare Coverage Gives a Growing Number of Patients Affordable Access

INSIGHTEC®, a global medical technology innovator of incisionless surgery, today announced Medicare benefit coverage by CGS Medicare and Palmetto GBA for MR-guided focused ultrasound (MRgFUS) for the treatment of essential tremor (ET). This brings the total number of states who cover the Neuravive treatment for medication-refractory ET to 25.

With this announcement, patients are now covered in Alabama, Georgia, North Carolina, South Carolina, Tennessee, Virginia, West Virginia, Kentucky and Ohio. Earlier this year, INSIGHTEC announced Medicare coverage for the procedure in Connecticut, Maine, New Hampshire, Rhode Island, Vermont, New York, Massachusetts, Illinois, Wisconsin, Minnesota, Indiana, Iowa, Kansas, Nebraska, Michigan and Missouri.

"2018 marks the year of Medicare reimbursement for incisionless focused ultrasound treatment for essential tremor," said Maurice R. Ferré, MD, Chief Executive Officer and Chairman of the Board of INSIGHTEC. "We're excited by this momentum and look forward to coverage for all Medicare patients in the U.S. in the near future."

"Focused ultrasound offers medication-refractory essential tremor patients tremor improvement with no incisions and minimal complications," said Dr. Vibhor Krishna, MBBS, The Ohio State University Wexner Medical Center.

In the United States, MR-guided focused ultrasound for the treatment of ET is available at the following institutions: Stanford University Medical Center (CA), Sperling Medical Group (FL), University of Maryland School of Medicine (MD), Brigham and Women's Hospital (MA), Mayo Clinic (MN), Weill Cornell Medical College (NY), NYU Langone Medical Center (NY), The Ohio State University Wexner Medical Center (OH), Penn Medicine (PA), UVA Health System (VA) and Swedish Neuroscience Institute (WA).

The status of coverage is available on the Medicare Coverage Database on the Centers for Medicare and Medicaid Services (CMS) website.

About INSIGHTEC
INSIGHTEC is a global medical technology innovator transforming patient lives through incisionless brain surgery using MR-guided focused ultrasound. The company's award-winning Exablate Neuro™ is used by neurosurgeons to perform the Neuravive™ treatment to deliver immediate and durable tremor relief for essential tremor patients. Research for future applications in the neuroscience space is underway in partnership with leading academic and medical institutions. INSIGHTEC is headquartered in Haifa, Israel, and Miami, Florida, with offices in Dallas, Tokyo and Shanghai.

For more information, please visit: http://www.insightec.com/

Forward-looking Statements
This press release contains forward-looking statements regarding, among other things, statements pertaining to expectations, goals, plans, objectives, and future events. INSIGHTEC intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934, and the Private Securities Reform Act of 1995. In some cases, forward-looking statements can be identified by the following words: "may," "can," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "promise," "continue," "ongoing," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements are based on the current estimates and assumptions of our management as of the date of this press release and are subject to risks, uncertainties, changes in circumstances, assumptions, and other factors that may cause actual results to differ materially from those indicated by forward-looking statements, many of which are beyond INSIGHTEC's ability to control or predict. Given these uncertainties, undue reliance should not be placed on these forward-looking statements. INSIGHTEC does not undertake any obligation to release publicly any updates or revisions to these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

"Exablate," and "Exablate Neuro," as well as the "INSIGHTEC" logo, whether standing alone or in connection with the word " INSIGHTEC" are protected trademarks of INSIGHTEC.

Contact details:
Alyssa Gustafsson
G&S Business Communications for INSIGHTEC
[email protected]
+1-917-595-3063

SOURCE INSIGHTEC